ImageneBio (IMA) AI Stock Analysis

• Market Cap: $92.14M
• Dividend Yield: N/A
• Average Volume (3M): 69.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: -100.00%
• EPS Growth: 45.48%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 11,181,676
• 10 Day Avg. Volume: 58,561
• 30 Day Avg. Volume: 69,515
• PEG Ratio: 0.52
• Price to Book (P/B): 7.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -20.64
• Enterprise Value/Market Cap: -0.27
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 3.03
• Enterprise Value/Ebitda: 0.46
• 1Y Price Target: $16.00
• Price Target Upside: 157.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: ―

Ikena Oncology's overall stock score of 41.2 reflects significant challenges in financial performance, including declining revenues and negative cash flow, which weigh heavily on the score. Technical analysis shows lackluster momentum, while the valuation is unattractive due to negative earnings. Improvements in revenue generation and profitability are crucial for a better financial outlook.

Positive Factors

Strong Cash Position

A strong cash position provides financial flexibility, allowing Ikena Oncology to invest in R&D and navigate periods of low revenue without immediate liquidity concerns.

Proprietary Platform

Ikena's proprietary platform for targeted oncology treatments positions it to potentially develop breakthrough therapies, offering a competitive edge in the biotech industry.

Low Debt Levels

Low debt levels reduce financial risk and interest obligations, allowing more resources to be allocated towards strategic growth initiatives and R&D.

Negative Factors

Declining Revenues

The absence of revenue growth poses a significant challenge, limiting the company's ability to fund operations and invest in future growth without external financing.

Negative Cash Flow

Negative cash flow indicates ongoing cash burn, necessitating reliance on external funding, which can dilute shareholder value and increase financial risk.

Profitability Challenges

Continuous profitability challenges hinder the company's ability to self-sustain, impacting its long-term viability and attractiveness to investors.

ImageneBio Business Overview & Revenue Model

Company Description

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

How the Company Makes Money

Ikena Oncology makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships and collaborations with other pharmaceutical companies, which may include milestone payments, research funding, and potential royalties on successfully developed and marketed drugs. Additionally, Ikena may earn income by out-licensing its drug candidates or technology platforms to other firms within the pharmaceutical industry. The company's revenue is also influenced by its ability to advance its drug candidates through clinical trials, obtain regulatory approvals, and successfully launch products into the market.

ImageneBio Financial Statement Overview

Summary

Ikena Oncology is struggling with profitability and revenue generation, impacting its income and cash flow statements negatively. The balance sheet shows some stability due to strong cash reserves and low debt, but historical negative equity highlights underlying financial challenges. The company needs to improve revenue generation and profitability to enhance financial health.

Income Statement

Ikena Oncology has faced declining revenues over recent years, with a revenue drop to zero in the latest period. The company consistently reports negative EBIT and net income, indicating profitability challenges. The lack of revenue growth and negative margins reflect financial instability.

Balance Sheet

The company maintains a strong cash position relative to its debt, with a low debt-to-equity ratio indicating manageable leverage. However, persistent negative equity in past years points to potential financial distress. The equity ratio has improved, yet the overall balance sheet strength remains modest.

Cash Flow

Ikena Oncology has improved its free cash flow from prior periods, but it remains negative, indicating continued cash burn. The operating cash flow is negative but has shown improvement, suggesting better cash management. Despite these improvements, reliance on external financing persists.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	3.50M	9.16M	15.62M	30.98M	9.19M
Gross Profit	-8.34M	3.50M	8.14M	-48.70M	-16.12M	-35.65M
EBITDA	-54.47M	-35.47M	-74.40M	-70.15M	-33.59M	-44.22M
Net Income	-45.29M	-36.57M	-68.17M	-68.77M	-34.12M	-44.26M
Balance Sheet
Total Assets	160.88M	141.51M	192.09M	172.26M	247.88M	168.40M
Cash, Cash Equivalents and Short-Term Investments	142.58M	124.39M	175.47M	156.95M	232.22M	162.49M
Total Debt	10.96M	7.52M	10.74M	5.69M	6.99M	186.00K
Total Liabilities	21.05M	15.58M	22.34M	25.29M	40.00M	269.45M
Stockholders Equity	139.83M	125.93M	169.76M	146.97M	207.88M	-101.05M
Cash Flow
Free Cash Flow	-46.89M	-46.00M	-80.16M	-75.54M	-62.01M	-38.59M
Operating Cash Flow	-46.89M	-46.00M	-79.74M	-74.11M	-60.25M	-37.83M
Investing Cash Flow	-3.99M	-34.90M	64.14M	-99.28M	-1.76M	2.92M
Financing Cash Flow	135.47M	0.00	75.98M	1.09M	131.74M	116.18M

ImageneBio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMA, the sentiment is Negative. The current price of 6.21 is below the 20-day moving average (MA) of 7.64, below the 50-day MA of 7.89, and below the 200-day MA of 12.99, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 26.23 is Positive, neither overbought nor oversold. The STOCH value of 0.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMA.

ImageneBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CSBR	56 Neutral	$83.50M	30.31	185.89%	―	10.11%	―
ADAG	52 Neutral	$80.12M	-2.64	-63.41%	―	-87.59%	11.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMA	41 Neutral	$92.14M	-1.08	-33.05%	―	-100.00%	45.48%
ALXO	39 Underperform	$78.18M	-0.66	-118.95%	―	―	31.98%
IMUX	37 Underperform	$81.67M	―	-398.50%	―	―	30.16%
PLRX	37 Underperform	$98.83M	-0.47	-64.27%	―	―	14.19%